University of Texas System

Xuping Xie

Pei-Yong Shi

Chao Shan

Jia Zhou

Jimin Xu

Jing Zou

The invention generally relates to the development of immunogenic compositions comprising a DNA copy of at least one live attenuated plus-sense single-stranded RNA virus genome, such as the genome of a live-attenuated Zika vims (ZIKV), Japanese encephalitis virus (JEV) or yellow fever vims (YFV). The immunogenic compositions can be used for treating or conferring protective immunity against diseases related to plus-sense single-stranded RNA viruses, e.g. for affording prolonged immunoprotection against such viruses and protective immunity is conferred at low diseases, e.g., as low as 300 or 500 ng after administration of a single pLAV dosage.

DNA plasmid-launched live-attanuated vaccines for plus-sense singel stranded RNA

A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2′,5(3H)-dione analogues, the use thereof and the preparation thereof.

Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2',5(3H)-dione analogues

The present invention discloses a live attenuated strain of Zika virus (ZIKV) having a deletion in the 3' untranslated region (3&#x2032;UTR) of the viral genome, which may affect viral RNA synthesis and sensitivity to type I interferon inhibition, but may not affect viral RNA translation. The present invention also discloses the use of these live attenuated ZIKV strains in the preparation of ZIKV vaccines and for providing immunoprotection against ZIKV infection and congenital ZIKV syndrome, particularly in pregnant females.

Live attenuated Zika virus with 3'UTR deletion, vaccine containing and use thereof

A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2&#x2032;,5(3H)-dione analogues, the use thereof and the preparation thereof.

Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2&#x2032;,5(3H)-dione analogues

Embodiments of the invention are directed to stable full-length cDNA clones of a clinical, Asian lineage ZIKV strain. Certain embodiments of the invention are directed to high-throughput assays for ZIKV and dengue virus (DENV) diagnosis.

Reverse genetics system of Zika virus

The invention generally relates to the development of variant Zika strains, cDNA clones and mRNA transcripts that contain specific mutations in the Zika ORF, and methods for producing high yields of Zika viruses ('ZIKVs') using these variant cDNA clones, transcripts and strains. The produced ZIKVs can be used for the manufacture of purified inactivated vaccines (PIVs), which may be useful for treating ZIKV-related diseases and for providing immunoprotection against ZIKV.

Growing community of inventors

Galveston, TX, United States of America

Xuping Xie